Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes: a systematic review and meta-analysis

ABSTRACT

Aim: To evaluate the efficacy and adverse effects of IDegLira and IGlarLixi treatment and to perform a comparison between two strategies.

Methods: The registration number is CRD42017053952. Randomized controlled trials of IGlarLixi treatment or IDegLira treatment compared with placebo or active hypoglycemic agents in type 2 diabetes were included.

Results: Eight trials were included. The absolute HbA1c change relative to baseline after IGlarLixi treatment was −1.50% with significance (95% CI, −1.89% to −1.12%, p < 0.01); the absolute HbA1c change after IDegLira treatment was −1.89% with significance (95% CI, −2.04% to −1.73%, p < 0.01). Comparisons between IGlarLixi treatment and IDegLira treatment indicated no significant differences between groups. The absolute weight change after IGlarLixi treatment significantly decreased (weighted mean difference (WMD), −0.62 kg; 95% CI, −0.93 to −0.31 kg, p = < 0.01), but the absolute weight change after IDegLira treatment was not significantly changed (WMD, −0.81 kg; 95% CI, −3.26 to 1.65 kg, p = 0.52). There were no significant differences between groups.

Conclusion: Glucose control of IGlarLixi treatment or IDegLira treatment was significantly lower than that at baseline. Comparisons between the two treatment groups indicated no significant differences between groups in absolute HbA1c changes or body weight changes relative to baseline.

KEYWORDS:

• IDegLira
• IGlarLixi
• HbA1c
• body weight

Acknowledgments

We thank for Dr. Lingli Zhou, Dr. Yifei Chen, Dr. Ling Chen and Prof. Xueyao Han during the study at Peking University People’s Hospital Endocrinology and Metabolism Department.

Authors’ contributions

LN Ji and XL Cai conceived and designed the systematic review protocol; XY Gao and WJ Yang performed the study selection and data extraction; XL Cai and XY Gao performed the statistical analyses; and XL Cai and LN Ji prepared the manuscript outlines and drafts. All authors contributed to the critical revision of manuscript drafts, as well as giving final approval for submitted manuscript content.

Declaration of interest

LN Ji has received fees for lecture presentations and for consulting from AstraZeneca, Merck, Novartis, Lilly, Roche, Sanofi-Aventis, NovoNordisk, Bayer and Takeda. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Supplemental data can be accessed here.

Additional information

Funding

This paper was not funded.